Response to Treatment with Intravenous Golimumab or Infliximab in Rheumatoid Arthritis Patients: PROMIS Results from the Real-World Observational Phase 4 AWARE Study

INTRODUCTION: To assess changes in the Patient-Reported Outcomes Measurement Information System (PROMIS(®)) outcomes related to social, mental, and physical well-being after approximately 1 year of intravenous (IV) golimumab or infliximab treatment in patients with rheumatoid arthritis (RA) using re...

Descripción completa

Detalles Bibliográficos
Autores principales: Bingham, Clifton O., Black, Shawn, Shiff, Natalie J., Xu, Stephen, Langholff, Wayne, Curtis, Jeffrey R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140242/
https://www.ncbi.nlm.nih.gov/pubmed/36820983
http://dx.doi.org/10.1007/s40744-023-00533-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140242/
https://www.ncbi.nlm.nih.gov/pubmed/36820983
http://dx.doi.org/10.1007/s40744-023-00533-5

Ejemplares similares